[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xu Zhi-yuan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100652479","phase-1-spatially-fractionated-radiotherapy-for-tumor-treatment-100652479",false,"NCT07774819","Spatially Fractionated Radiotherapy for Tumor Treatment","Spatially Fractionated Radiotherapy for Bulky or Refractory Solid Tumors: Efficacy and Toxicity","Inclusion Criteria:\n\n* Patients with a bulky solid tumor with a maximum diameter \\>4 cm or a refractory solid tumor.\n\nExclusion Criteria:\n\n* Tumors involving hollow viscera that are considered to have a clinically significant risk of bleeding or perforation.\n* Patients with impaired consciousness or who are unable to care for themselves.","ALL","18 Years","75 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.",[28],"Radiotherapy-Induced Immune Priming",[30,31],"Spatially fractionated radiotherapy","Bulky tumor","RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":36},"2024-12-19",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"Xu Zhi-yuan","OTHER",""]